Evidence map›Paper›PMID 41612885›Full record

Trial reportFuture oncology (London, England)2026

JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.

Lillian L Siu, Barbara Burtness, Kevin Harrington, Amanda Psyrri, Nabil F Saba, Makoto Tahara, Gary Carlson, Arindam Dhar, Matthew Grimshaw, Lei Hua and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06256588 (A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06256588 phase3recruitingnot on this map

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

TypeinterventionalSponsorGlaxoSmithKlineRan2024 to 2029Enrolled864ConditionsNeoplasms, Head and NeckArmsDostarlimab, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lillian L SiuDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Barbara BurtnessDepartment of Internal Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Kevin HarringtonDivision of Radiotherapy and Imaging, The Institute of Cancer Research/Royal Marsden Hospital, London, UK.
Amanda PsyrriSecond Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, Athens, Greece.
Nabil F SabaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Gary CarlsonGSK, Waltham, MA, USA.
Arindam DharGSK, Collegeville, PA, USA.
Matthew GrimshawGSK, London, UK.
Lei HuaGSK, Waltham, MA, USA.
Riham IadevaiaGSK, Waltham, MA, USA.
Davinder ThetiGSK, London, UK.
Gordana VlahovicGSK, Waltham, MA, USA.
Jean-Pascal MachielsDepartment of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHead and neck squamous cell carcinoma (HNSCC) accounts for approximately 5% of cancer cases worldwide, with more than half of patients presenting with locally advanced (LA) disease. Treatment of LA HNSCC is multimodal and may include concomitant cisplatin-based chemoradiotherapy (CRT) or surgery; however, recurrence rates are high, and there is an unmet need for new treatments. Immune checkpoint inhibitors that target programmed death receptor-1 (PD-1) are standard of care for recurrent/metastatic HNSCC, but outcomes for anti-PD-1 and anti-PD-(ligand [L])1 therapies with CRT in LA HNSCC have been variable. Dostarlimab, an anti-PD-1 therapy approved in advanced endometrial cancer and mismatch repair-deficient solid tumors is being investigated across other tumor types, including HNSCC. JADE is a global, multicenter, double-blind, placebo-controlled, randomized phase 3 study evaluating the efficacy and safety of dostarlimab as post-cisplatin-based CRT sequential therapy in patients with LA unresected PD-L1-expressing HNSCC. JADE seeks to overcome the limitations of previous studies by incorporating both PD-L1 selection and solely sequential administration of dostarlimab soon after CRT.

methodsThe primary endpoint is event-free survival, with overall survival as a key secondary endpoint; safety and tolerability, pharmacokinetics, immunogenicity, biomarkers, and patient-reported outcomes will also be assessed. CLINICAL

trial registrationwww.clinicaltrials.gov identifier is NCT06256588.

Indexed as

Antibodies, Monoclonal, HumanizedHead and Neck NeoplasmsImmune Checkpoint InhibitorsSquamous Cell Carcinoma of Head and NeckAdultAgedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenChemoradiotherapyCisplatinDouble-Blind MethodFemaleHumansMiddle AgedNeoplasm StagingAntibodies, Monoclonal, HumanizedB7-H1 AntigenCisplatindostarlimabImmune Checkpoint InhibitorschemoradiotherapydostarlimabHNSCCJADElocally advancedPD-1PD-L1-positiveunresected

Identifiers

PMID41612885
PMCPMC12867452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.